REG - Hikma Pharmaceutical - Notification of major interest in shares <Origin Href="QuoteRef">HIK.L</Origin>

Hikma PharmaceuticalsAnnouncement

28/01/2015 01:59

RNS Number : 7547C
Hikma Pharmaceuticals Plc
21 January 2015
Notification of major interests in shares
LONDON, 21 January 2015 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (DIFX: HIK), the fast growing multinational pharmaceuticals group, announces as follows:
1
Identity of the issuer or the underlying issuer of existing shares to which the voting rights are attached
Hikma Pharmaceuticals PLC
2
Reason for the notification


An acquisition or disposal of voting rights
Yes

An acquisition or disposal of financial instruments which may result in the acquisition of shares already issues to which voting rights are attached
No

An event changing the breakdown of voting rights
No

Other (please specify): Compliance with the Transparency Directive
No
3
Full name of the person subject to the notification obligation
FMR LLC
4
Full name of shareholders 
See attached schedule
5
Date of the Transaction (and date on which the threshold crossed is reached differently)
19 January 2015
6
Date on which the issuer notified
20 January 2015
7
Threshold that is crossed
5% 
8
Notified details
See A, B & C below



A. Voting rights attached to shares
Class type of shares (if possible using the ISIN code)
Situation previous to the triggering transaction
Resulting situation after the triggering transaction
Number of shares
Number of voting rights
Number of shares
Number of voting rights
% of voting rights
Direct
Indirect
Direct
Indirect
Direct 
Indirect
Ordinary Shares (0.10 GBP)
GB00B0LCW083
10,043,409
10,043,409
-
9,893,409
-
9,893,409
-
4.98
B. Qualifying Financial instruments
Resulting situation after the triggering transaction
Type of financial instrument
Expiration Date
Exercise/Conversion Period/Date
Number of voting rights that may be acquired if the instrument if exercised/converted
% of voting rights
-
-
-
-
-
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial instrument
Exercise Price
Expiration Date
Exercise/Conversion Period/Date
Number of voting rights instrument refers to
% of voting rights
Nominal 
Delta
-
-
-
-
-
-
-
Total A+B+C
Number of Voting rights
% of voting rights
9,893,409
4.99%
9
Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable

Proxy Voting
10
Name of the proxy holder
Custodian
Day to Day IM
Total
BANK OF NEW YORK BRUSSELS (C)
PGALLC-PYRAMIS GLOBAL ADVISORS, LLC
8,051
BANK OF NEW YORK MELLON
PGALLC-PYRAMIS GLOBAL ADVISORS, LLC
156,712
BROWN BROTHERS HARRIMAN AND CO
FMR UK-FIDELITY MANAGEMENT & RESEARCH (U.K.) INC.
25,001

PGALLC-PYRAMIS GLOBAL ADVISORS, LLC
68,425

PGATC-PYRAMIS GLOBAL ADVISORS TRUST COMPANY
822,664
CIBC MELLON TRUST (C)
PGALLC-PYRAMIS GLOBAL ADVISORS, LLC
19,726
CITIBANK NA, HONG KONG BR (S)
PGALLC-PYRAMIS GLOBAL ADVISORS, LLC
21,821
JP MORGAN, BOURNEMOUTH (C)
PGALLC-PYRAMIS GLOBAL ADVISORS, LLC
13,981

PGATC-PYRAMIS GLOBAL ADVISORS TRUST COMPANY
219,471
JPMORGAN CHASE BANK
FMR UK-FIDELITY MANAGEMENT & RESEARCH (U.K.) INC.
162,476

FMRC-FMR CO., INC
3,337,724

PGALLC-PYRAMIS GLOBAL ADVISORS, LLC
42,456

PGATC-PYRAMIS GLOBAL ADVISORS TRUST COMPANY
83,696
MELLON BANK NA (C)
PGALLC-PYRAMIS GLOBAL ADVISORS, LLC
388,798
NATIONAL BANK TRUST (C)
PGATC-PYRAMIS GLOBAL ADVISORS TRUST COMPANY
20,223
NOMURA TRUST AND BANKING (C)
PGALLC-PYRAMIS GLOBAL ADVISORS, LLC
294
NORTHERN TRUST CO (C)
FMR UK-FIDELITY MANAGEMENT & RESEARCH (U.K.) INC.
2,865,472

PGATC-PYRAMIS GLOBAL ADVISORS TRUST COMPANY
371,824
STATE STREET BANK AND TR CO
FMRC-FMR CO., INC
244,499

PGALLC-PYRAMIS GLOBAL ADVISORS, LLC
453,252

PGATC-PYRAMIS GLOBAL ADVISORS TRUST COMPANY
543,597
US BANK NA (C)
PGALLC-PYRAMIS GLOBAL ADVISORS, LLC
23,246
Grand Total

9,893,409
11
Number of voting rights proxy holder will cease to hold
N/A
12
Date on which proxy holder will cease to hold voting rights
N/A
13
Additional Information

14
Contact name:
Peter Speirs, Company Secretary
15
Contact telephone number:
020 7399 2772
- ENDS -
About Hikma
Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2013, Hikma achieved revenues of $1,365 million and profit attributable to shareholders of $212 million. 

This information is provided by RNS
The company news service from the London Stock Exchange
  END
HOLBBMBTMBBTBFA